| Total (n = 75) | Nortriptyline (n = 53) | Clomipramine (n = 18) | Imipramine (n = 4) | p-value†|
---|---|---|---|---|---|
Patient characteristics | |||||
 Female, n (%) | 39 (52) | 27 (51) | 9 (50) | 3 (75) | 0.64 |
 Age, mean (SD) | 54.4 (16.6) | 54.5 (17.1) | 52.6 (15.1) | 60.8 (18.9) | 0.21 |
 Hospitalized, n (%) | 44 (59) | 33 (62) | 9 (50) | 2 (50) | 0.62 |
 Psychotic depression, n (%) | 16 (21) | 12 (23) | 4 (22) | 0 (0) | 0.56 |
TCA selection | |||||
 Age > 65 years, n (%) | 21 (28) | 17 (32) | 3 (17) | 1 (25) | 0.44 |
 Comorbid anxiety‡, n (%) | 7 (9) | 5 (9) | 2 (11) | 0 (0) | 0.79 |
TCA dosing | |||||
 Initial dose (mg/day), mean (SD) | 40.3 (19.5) | 35.2 (14.1) | 58.2 (23.4) | 27.5 (16.6) | 0.001** |
 Max. dose§ (mg/day), mean (SD) | 105.1 (39.6) | 90.3 (31.1) | 133.3 (32.4) | 175.0 (28.9) | < 0.001** |
 TDM conducted§, n (%) | 67 (89) | 46 (87) | 17 (94) | 4 (100) | 0.51 |
 Therapeutic concentrations§, n (%) | 53 (71) | 42 (79) | 9 (50) | 2 (50) | 0.040* |
 Pharmacogenetics¶, n (%) | 5 (7) | 5 (9) | 0 (0) | 0 (0) | 0.33 |